Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany

被引：0
作者：
Stargardt, T. [1 ]
Brinkmann, C. [1 ]
Baum, R. P. [2 ,3 ]
机构：
[1] Univ Hamburg, Hamburg Ctr Hlth Econ, Hamburg, Germany
[2] Int Ctr Precis Oncol ICPO, Wiesbaden, Germany
[3] CURANOSTICUM, Wiesbaden, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0988
引用
收藏
页码：S827 / S827
页数：1
相关论文
共 50 条
  • [31] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Khreish, Fadi
    Ebert, Niklas
    Ries, Martin
    Maus, Stephan
    Rosar, Florian
    Bohnenberger, Hendrik
    Stemler, Tobias
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (03) : 721 - 728
  • [32] Extended radioligand therapy with Lu-177-PSMA-617 in patients with advanced metastatic castration-resistant prostate cancer
    Mader, N.
    Baumgarten, J.
    Groener, D.
    Ngoc, C. Nguyen
    Davis, K.
    Banek, S.
    Tselis, N.
    Happel, C.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S489 - S489
  • [33] 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer
    Fendler, Wolfgang P.
    Kratochwil, Clemens
    Ahmadzadehfar, Hojjat
    Rahbar, Kambiz
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Luetzen, Ulf
    Prasad, Vikas
    Heinzel, Alexander
    Heuschkel, Martin
    Ruf, Juri
    Bartenstein, Peter
    Krause, Bernd J.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (03): : 123 - 128
  • [34] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Heinzel, Alexander
    Boghos, Dima
    Mottaghy, Felix M.
    Gaertner, Florian
    Essler, Markus
    von Mallek, Dirk
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1054 - 1062
  • [35] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Alexander Heinzel
    Dima Boghos
    Felix M. Mottaghy
    Florian Gaertner
    Markus Essler
    Dirk von Mallek
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1054 - 1062
  • [36] PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Spain, Lavinia Anne
    Horvath, Lisa
    Crumbaker, Megan
    Anton, Angelyn
    Wallace, Roslyn
    Pasam, Anupama
    Bressel, Mathias
    Cassidy, Erin
    Banks, Patricia
    Dhiantravan, Nattakorn
    Akhurst, Timothy J.
    Kumar, Aravind Ravi
    Alipour, Ramin
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] 177Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment
    Sahin, Ertan
    Elboga, Umut
    Cimen, Ufuk
    Okuyan, Merve
    Cayirli, Yusuf Burak
    CURRENT RADIOPHARMACEUTICALS, 2024, 17 (04) : 356 - 363
  • [38] Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
    Mader, Nicolai
    Groener, Daniel
    Tselis, Nikolaos
    Banek, Severine
    Nagarajah, James
    Grunwald, Frank
    Sabet, Amir
    CANCERS, 2021, 13 (16)
  • [39] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [40] Phase 3 Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (VISION)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 3 - 5
12345